A drug aimed at alcoholism is one step closer to hitting your corner pharmacy. Nalmefene apparently obliterates the pleasure of drinking booze by targeting -and blocking- specific receptors in the brain .  In a six-month study that included  604 patients in multiple European countries,  the drug cut down alcohol consumption by half. Clinical trials are underway in Europe.

It could be a boon for anyone who likes the sauce a bit too much.   However, you won’t see a big marketing push by any of the big Pharmaceutical companies, since it’s considered a generic drug in the US. Plus, it has some uncomfortable side effects, including drowsiness, hypertension, tachycardia, dizziness, nausea, and vomiting.